Version 1
: Received: 10 October 2023 / Approved: 10 October 2023 / Online: 11 October 2023 (07:43:18 CEST)
How to cite:
Zakari, S.; Bella-Omunagbe, M.; Zakari, H.; O. Ogbu, C.; Ejim Uti, D.; Ogunlana, O. O. The Role of SRC-3 in Prostate Cancer Progression and Implications for Therapeutic Targeting: A Systematic Review. Preprints2023, 2023100577. https://doi.org/10.20944/preprints202310.0577.v1
Zakari, S.; Bella-Omunagbe, M.; Zakari, H.; O. Ogbu, C.; Ejim Uti, D.; Ogunlana, O. O. The Role of SRC-3 in Prostate Cancer Progression and Implications for Therapeutic Targeting: A Systematic Review. Preprints 2023, 2023100577. https://doi.org/10.20944/preprints202310.0577.v1
Zakari, S.; Bella-Omunagbe, M.; Zakari, H.; O. Ogbu, C.; Ejim Uti, D.; Ogunlana, O. O. The Role of SRC-3 in Prostate Cancer Progression and Implications for Therapeutic Targeting: A Systematic Review. Preprints2023, 2023100577. https://doi.org/10.20944/preprints202310.0577.v1
APA Style
Zakari, S., Bella-Omunagbe, M., Zakari, H., O. Ogbu, C., Ejim Uti, D., & Ogunlana, O. O. (2023). The Role of SRC-3 in Prostate Cancer Progression and Implications for Therapeutic Targeting: A Systematic Review. Preprints. https://doi.org/10.20944/preprints202310.0577.v1
Chicago/Turabian Style
Zakari, S., Daniel Ejim Uti and Olubanke O. Ogunlana. 2023 "The Role of SRC-3 in Prostate Cancer Progression and Implications for Therapeutic Targeting: A Systematic Review" Preprints. https://doi.org/10.20944/preprints202310.0577.v1
Abstract
Background: Prostate cancer remains a significant global health concern, and understanding the molecular drivers of this disease is crucial for developing effective diagnostic and therapeutic strategies. Steroid Receptor Coactivator-3 (SRC-3), a member of the SRC family, has emerged as a key player in prostate cancer pathogenesis. This review comprehensively examine the role of SRC-3 in prostate cancer, encompassing molecular mechanisms, clinical implications, and therapeutic opportunities. Methods: A systematic literature search following PRISMA guidelines was conducted in PubMed, PMC, and other relevant databases to identify studies that investigate SRC-3 in prostate cancer. A total of 67 articles were selected based on predetermined inclusion criteria. Results: 785 articles were retrieved from databases using specific keywords and MeSH terms related to SRC-3 and Prostate Cancer. After removing 461 duplicates, 260 articles were excluded based on title and abstract review. Subsequently, a comprehensive screening by three researchers resulted in 47 relevant articles for this systematic review. We summarize its contributions to AR-mediated transcriptional regulation, tumor growth, and metastasis. Evidence suggests that SRC-3 expression correlates with prostate cancer aggressiveness, disease recurrence, and poor patient outcomes. Its potential as a diagnostic biomarker and therapeutic target is explored, offering insights into personalized medicine approaches. Conclusions: SRC-3 plays a pivotal role in prostate cancer, influencing disease progression and clinical outcomes. Understanding the molecular intricacies of SRC-3 in prostate cancer offers new opportunities for precision medicine and innovative therapeutic approaches. This review provides a comprehensive overview of SRC-3's involvement in prostate cancer, emphasizing its clinical relevance and potential as a therapeutic target, ultimately contributing to improved patient care in the era of personalized oncology.
Keywords
Androgen Receptor, AR signaling, Prostate cancer, SRC-3, Therapeutics
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.